Compare BBVA & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBVA | GSK |
|---|---|---|
| Founded | 1857 | 1715 |
| Country | Spain | United Kingdom |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.0B | 98.9B |
| IPO Year | N/A | N/A |
| Metric | BBVA | GSK |
|---|---|---|
| Price | $23.39 | $50.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.2M | ★ 3.1M |
| Earning Date | 01-29-2026 | 02-04-2026 |
| Dividend Yield | 2.77% | ★ 3.38% |
| EPS Growth | 7.95 | ★ 118.57 |
| EPS | ★ 2.04 | 1.79 |
| Revenue | $37,116,038,958.00 | ★ $43,237,357,842.00 |
| Revenue This Year | $17.82 | $6.70 |
| Revenue Next Year | $4.98 | $5.10 |
| P/E Ratio | ★ $11.72 | $27.45 |
| Revenue Growth | ★ 6.03 | 2.73 |
| 52 Week Low | $9.85 | $31.72 |
| 52 Week High | $24.19 | $49.63 |
| Indicator | BBVA | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 60.21 | 67.52 |
| Support Level | $23.31 | $48.59 |
| Resistance Level | $24.19 | $49.40 |
| Average True Range (ATR) | 0.30 | 0.56 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 57.14 | 75.11 |
Despite its Spanish origins, Banco Bilbao Vizcaya Argentaria generates only around one-fourth of its profits in Spain. We expect that on a normalized basis, BBVA's market-leading Mexican bank should contribute half of its earnings, while its Turkish operation should account for another 15%. The balance of BBVA's earnings comes from smaller operations in South America. BBVA is overwhelmingly a retail and commercial bank, with corporate and investment banking forming a minor part of the overall business. BBVA also offers insurance and investment products through its banking networks.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.